COMBINED INFUSION OF ANTI-CD19 AND ANTI-BCMA CAR-T CELLS AFTER ASCT IN THE FRONT LINE WAS SUPERIOR TO SINGLE ASCT FOR HIGH RISK MM

EHA Library, Xiaolan Shi, 294852

HOW TO DEFINE AND PREDICT UNSUSTAINED CR IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: A SUB ANALYSIS OF THE GEM2012MENOS65 TRIAL

EHA Library, Ana Jiménez Ubieto, 294853

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) – OUTCOMES BY PRIOR THERAPIES

EHA Library, Sagar Lonial, 294854

CARFILZOMIB, DEXAMETHASONE (KD) AND DARATUMUMAB VERSUS KD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE CANDOR STUDY BY NUMBER OF PRIOR LINES OF THERAPY AND PRIOR THERAPIES

EHA Library, Katja Weisel, 294855

UPDATED RESULTS FROM BELLINI, A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Shaji K. Kumar, 294856

UPDATED RESULTS FROM A PHASE 1/2 STUDY OF VENETOCLAX IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE, +/- BORTEZOMIB, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jonathan L. Kaufman, 294857

High Levels of Circulating Plasma Cells Predict Low Rate of Sustained Minimal Residual Disease Negativity in Transplant Eligible Multiple Myeloma Patients Treated with Novel Agents

EHA Library, Luca Bertamini, 294858

S-ERMM: A SIMPLIFIED SCORE TO PREDICT EARLY RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA. ANALYSIS FROM A POOLED DATASET OF 2190 PATIENTS.

EHA Library, Gian Maria Zaccaria, 294859

COMPARISON OF NEXT GENERATION SEQUENCING AND NEXT GENERATION FLOW KEY METRICS IN MULTIPLE MYELOMA MRD ASSESSMENT: DATA FROM THE GMMG HD6 TRIAL

EHA Library, Katharina Kriegsmann, 294860

PROGNOSTIC IMPACT OF TRISOMIES WITH 1Q GAIN OR 13Q DELETION BY FISH IN PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Harsh Parmar, 294861

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY – PRIMARY AND SUBGROUP ANALYSIS

EHA Library, PAUL RICHARDSON, 294862

QIP-MASS SPECTROMETRY INCLUDING FREE LIGHT CHAINS IN HIGH-RISK MYELOMA PATIENTS ENROLLED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MRD DISEASE IMWG RESPONSE ASSESSMENT

EHA Library, Noemi Puig, 294863

DARATUMUMAB + BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: BASELINE SLIMCRAB-BASED SUBGROUP ANALYSIS OF CASSIOPEIA

EHA Library, Cyrille Touzeau, 294864

SAFETY AND TOLERABILITY OF SINGLE-AGENT BELANTAMAB MAFODOTIN IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: POOLED DATA FROM DREAMM-1 AND DREAMM-2

EHA Library, Suzanne Trudel, 294865

PHASE II CLINICAL TRIAL (EMN-ALLORIC 2010) OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) FOR HIGH RISK (HR) MULTIPLE MYELOMA (MM).

EHA Library, Marta Reinoso Segura, 294866

OVER TEN YEARS OF F/U FOR PHASE 3 TRIAL IN SMOLDERING MYELOMA AT HIGH RISK OF PROGRESSION TO MYELOMA: SUSTAINED TTP AND OS BENEFIT WITH RD VERSUS NO TREATMENT

EHA Library, María-Victoria Mateos, 294867

REAL-WORLD MANAGEMENT OF PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS IN EUROPE: A RETROSPECTIVE OBSERVATIONAL MULTICENTER STUDY BY EUROPEAN MYELOMA NETWORK (EMN)

EHA Library, Efstathios Kastritis, 294868

IMPACT OF DARATUMUMAB IN THE TREATMENT OF MULTIPLE MYELOMA ACCORDING TO CYTOGENETIC RISK

EHA Library, Luciano J. Costa, 294869

PHASE I, OPEN-LABEL STUDY OF PANOBINOSTAT, LENALIDOMIDE, BORTEZOMIB + DEXAMETHASONE IN RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jacob P. Laubach, 294870

HYPOGAMMAGLOBINEMIA AND INCREASED INFECTION RATES ASSOCIATED WITH DARATUMUMAB THERAPY IN MULTIPLE MYELOMA: WORSE WITH -PROTEASOME INHIBITOR COMPARED TO IMID-BASED COMBINATIONS

EHA Library, Roy Vitkon, 294871

DREAMM-4: EVALUATING SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Ajay Nooka, 294872

A SIMPLE SCORE TO PREDICT EARLY SEVERE INFECTION RISK IN PATIENTS WITH MULTIPLE MYELOMA TRANSPLANT AND NON-TRANSPLANT CANDIDATES

EHA Library, Cristina Encinas, 294873

OPTIMISMM SUBANALYSIS: POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

EHA Library, Meletios Dimopoulos, 294874

AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NO TRANSPLANTATION IN PATIENTS ABOVE 70 WITH MULTIPLE MYELOMA

EHA Library, Christopher Lemieux, 294875

BASELINE AND POSTINFUSION PHARMCODYNAMIC BIOMARKERS OF SAFETY AND EFFICACY IN PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE KARMMA STUDY

EHA Library, Justine Dell’Aringa, 294876

MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) EVALUATION: RESULTS OF THE FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Stefania Oliva, 294877

CARFILZOMIB IN COMBINATION WITH EITHER RD OR TD OVERCOMES THE NEGATIVE IMPACT OF HR CYTOGENETICS IN NDMM. INTERIM EFFICACY ANALYSIS OF COMBINED DATA OF KRD VS KTD FOLLOWED BY K MAINTENANCE OR CONTROL

EHA Library, Heinz Ludwig, 294878

CHARACTERIZATION OF RELAPSE AND SECOND-LINE THERAPY IN LENALIDOMIDE-REFRACTORY PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE 3 FIRST TRIAL SUBANALYSIS

EHA Library, Salomon Manier, 294879

ESTIMATING THE NUMBER OF US PATIENTS WITH MULTIPLE MYELOMA AT DIFFERENT LINES OF TREATMENT

EHA Library, Feng Wang, 294880

EFFICACY OF MAINTENANCE AND CONTINUOUS THERAPY IN PATIENTS WITH UNTREATED MULTIPLE MYELOMA: INDEPENDENT NETWORK META-ANALYSIS

EHA Library, Alexander Luchinin, 294881

NUMERIC ABNORMALITIES OF 1Q21 IDENTIFY AN ULTRA HIGH RISK GROUP OF MYELOMA PATIENTS

EHA Library, Magdalini Migkou, 294882

EVALUATION OF MINIMAL RESIDUAL DISEASE (MRD) BY NEXT GENERATION SEQUENCING (NGS) AND MASS SPECTROMETRY (MS) IN PHASE II TRIALS OF NEWLY-DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Jagoda Jasielec, 294883

GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN MULTIPLE MYELOMA (MM) PATIENTS (PTS) IN INSIGHT MM: IMPACT ON HEALTHCARE RESOURCE UTILIZATION (HRU) AND OVERALL SURVIVAL (OS)

EHA Library, Michael A. Thompson, 294884

THE ROLE OF AGE >80 IN DEFINING FRAIL PATIENTS: AN ANALYSIS FROM THE IMWG FRAILTY SCORE COHORT

EHA Library, Mattia D'Agostino, 294885

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EFFICACY OUTCOMES FOR IDECABTAGENE VICLEUCEL FROM THE KARMMA STUDY VS SELINEXOR PLUS DEXAMETHASONE (STORM PART 2) AND BELANTAMAB MAFODOTIN (DREAMM-2)

EHA Library, Paula Rodríguez-Otero, 294886

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY AND/OR INTOLERANT TO ANTI-CD38 MABS

EHA Library, Sagar Lonial, 294887

CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE

EHA Library, Boris Gorsh, 294888

MASS SPECTROMETRY FREE LIGHT CHAIN ASSESSMENT FOR COMPREHENSIVE MONOCLONAL PROTEIN EVALUATION DURING MYELOMA MONITORING

EHA Library, Ellen Jenner, 294889

DARATUMUMAB WITH IXAZOMIB AND DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED PRIOR TREATMENT WITH A LENALIDOMIDE-BASED REGIMEN: DESIGN AND FIRST RESULTS OF THE PHASE 2 DARIA STUDY

EHA Library, Evangelos Terpos, 294890

IFM 2012-03 FINAL ANALYSIS, CARFILZOMIB MAINTENANCE FOR NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Arthur Bobin, 294891

EVALUATION OF MINIMAL RESIDUAL DISEASE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE: BELLINI STUDY ANALYSES

EHA Library, Philippe Moreau, 294892

IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS) TREATED VIA AN EARLY ACCESS PROGRAM (EAP) IN EUROPE: THE ‘USE VIA EARLY ACCESS TO IXAZOMIB' (UVEA-IXA) STUDY

EHA Library, Heinz Ludwig, 294893

NEXT-GENERATION SEQUENCING OF VJ LIGHT CHAIN REARRANGEMENTS IN CELL-FREE DNA FOR MONITORING MULTIPLE MYELOMA

EHA Library, Elisabeth Mack, 294894

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS

EHA Library, Meral Beksac, 294895

DARATUMUMAB BASED THERAPY FOR PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE

EHA Library, Efstathios Kastritis, 294896

LENALIDOMIDE AND DEXAMETHASONE PLUS OR MINUS CLARYTHROMYCIN IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: UPDATED RESULTS OF THE GEM-CLARIDEX TRIAL

EHA Library, Noemi Puig, 294897

ROLE OF SERUM FREE LIGHT CHAIN ASSAY FOR DEFINING RESPONSE AND PROGRESSIVE DISEASE IN IMMUNOGLOBULIN SECRETORY MULTIPLE MYELOMA

EHA Library, Paola Tacchetti, 294898

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (POMCIDEX), FOR THE TREATMENT OR RELAPSE AND REFRACTORY MULTIPLE MYELOMA (RRMM): REAL-WORLD ANALYSIS OF THE PETHEMA-GEM EXPERIENCE.

EHA Library, Paula Rodríguez-Otero, 294899

UPDATES FROM A PHASE IB STUDY OF ISATUXIMAB, BORTEZOMIB AND DEXAMETHASONE PLUS CYCLOPHOSPHAMIDE OR LENALIDOMIDE IN TRANSPLANT INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Enrique Maria Ocio San Miguel, 294900

EFFICACY AND SAFETY OF DARATUMUMAB WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: PRELIMINARY RESULTS OF THE PHASE 2 DARE STUDY

EHA Library, Efstathios Kastritis, 294901

CORRELATION OF TUMOR BCMA EXPRESSION WITH RESPONSE AND ACQUIRED RESISTANCE TO IDECABTAGENE VICLEUCEL IN THE KARMMA STUDY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Nathan Martin, 294902

CORRELATION AND PROGNOSTIC VALUE OF QUANTIFICATION OF TUMOR VOLUME BY BONE MARROW BIOPSY, METABOLIC TUMOR VOLUME, AND TOTAL DIFFUSION VOLUME IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Toshiki Terao, 294903

MOBILIZATION OF AUTOLOGOUS STEM CELLS UNDER INDUCTION THERAPY WITH ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-KRD) IN HIGH-RISK MYELOMA PATIENTS: FIRST RESULTS OF THE GMMG-CONCEPT TRIAL

EHA Library, Anne-Marie Asemissen, 294904

PHASE 3 STUDY OF DARATUMUMAB/BORTEZOMIB/DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB/DEXAMETHASONE (VD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MMY3009 (LEPUS)

EHA Library, Xiaojun Huang, 294905

NEUTROPHILS-TO-LYMPHOCYTE RATIO AND IGM CONCENTRATION CAN PREDICT TIME TO PROGRESSION IN PATIENTS AFFECTED BY NON-IGM MGUS: RESULTS FROM A RETROSPECTIVE STUDY AT A SINGLE INSTITUTION

EHA Library, ALESSANDRA ROMANO, 294906

AL AMYLOIDOSIS SCREENING USING ABDOMINAL FAT PAD BIOPSY AND NT-PROBNP LEVELS IN MGUS PATIENTS: A RETROSPECTIVE REVIEW OF LOCAL EXPERIENCE

EHA Library, Holly Lee, 294907

CLINICAL PREDICTORS OF PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH ANTI-BCMA CAR-T CELLS

EHA Library, Sandy Wong, 294908

FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY FOR OPTIMIZING MELPHALAN, PREDNISOLONE AND BORTEZOMIB IN TRANSPLANT-INELIGIBLE UNTREATED MULTIPLE MYELOMA: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1105)

EHA Library, Dai Maruyama, 294909

DYNAMICS IN THE CHOICE OF TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA – RESULTS FROM THE MYRIAM REGISTRY

EHA Library, Monika Engelhardt, 294911

THE IMPACT OF CHANGED TREATMENT PATTERNS IN MULTIPLE MYELOMA ON HEALTH-ECONOMIC COSTS, MYELOMA COMPLICATIONS AND SURVIVAL; A POPULATION BASED COMPARISON BETWEEN TWO TIME PERIODS IN DENMARK.

EHA Library, Louise Hur Hannig, 294912

THROMBOTIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 294913

TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM THE CONNECT® MM REGISTRY

EHA Library, Hans Lee, 294914

IXAZOMIB-DEXAMETHASONE VS PHYSICIAN'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY SYSTEMIC AL AMYLOIDOSIS (AL) BY PRIOR PROTEASOME INHIBITOR EXPOSURE IN THE PHASE 3 TOURMALINE-AL1 TRIAL

EHA Library, Efstathios Kastritis, 294915

PREDICTORS OF EARLY RELAPSE IN YOUNG MULTIPLE MYELOMA PATIENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

EHA Library, Francesca Gay, 294916

AN INTACT GUT MICROBIOME PROTECTS GENETICALLY PREDISPOSED MICE AGAINST LEUKEMIA

EHA Library, Carolina Vicente-Dueñas, 294920

POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG

EHA Library, Peter Borchmann, 294921

TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY 'FORUM' ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

EHA Library, C Peters, 294922

NETRIN-1 REGULATES HEMATOPOIETIC STEM CELL DORMANCY AND FUNCTION VIA ITS RECEPTOR NEOGENIN WITH IMPLICATIONS FOR STEM CELL AGEING

EHA Library, Simon Renders, 294923

A NOVEL ROLE FOR IRON REGULATORY PROTEINS IN HEMATOPOIESIS

EHA Library, Bruno Galy, 294924

INDUCIBLE PHASE SEPARATION OF GSK3A MEDIATES ASPARAGINASE RESISTANCE IN ACUTE LEUKEMIAS

EHA Library, Laura Hinze, 294925

MEF2C DRIVES A MIXED PHENOTYPE ETP-ALL BY ACTIVATING B CELL GENES IN AN EARLY T CELL CONTEXT

EHA Library, Kirsten Canté-Barrett, 294926

BETTING ON PRC2 ALTERATION IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Guillaume Andrieu, 294927

MLL-AF4 RECRUITS H3K79ME2 VIA PAF1 DURING LEUKAEMIC TRANSFORMATION IN A NOVEL MODEL OF HUMAN FETAL LIVER-DERIVED T(4;11) INFANT ALL

EHA Library, Siobhan Rice, 294928

LONGITUDINAL MULTI-OMICS ANALYSIS OF 13 MATCHED SAMPLE PAIRS COLLECTED FROM PEDIATRIC T-CELL LEUKEMIA PATIENTS AT INITIAL DIAGNOSIS AND AT RELAPSE

EHA Library, Paulina Richter-Pechanska, 294929

RECURRENT PAX5 FUSIONS IN MLL-GERMLINE INFANT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Giovanni Cazzaniga, 294930

SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520

EHA Library, Matteo Marchesini, 294931

TOWARDS MOLECULAR STRATIFICATION OF PAEDIATRIC T-CELL LYMPHOBLASTIC LYMPHOMAS BASED ON MINIMAL DISSEMINATED DISEASE AND NOTCH1/FBXW7 MUTATIONAL STATUS: THE FRENCH EURO-LB02 EXPERIENCE

EHA Library, Amelie Trinquand, 294932

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

EHA Library, Hui Wang, 294933

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING DASATINIB-BASED TWO-STEP INDUCTION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF THE JALSG PH+ALL213 STUDY

EHA Library, Isamu Sugiura, 294934

FIRST-IN-HUMAN, UNIVERSAL ANTI-CD7 CAR-T THERAPY FOR RELAPSED AND REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R T-ALL)

EHA Library, Xinxin Wang, 294935

VENETOCLAX AND NAVITOCLAX IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

EHA Library, Elias Jabbour, 294936

IMPROVED OUTCOME FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) AND AN ABL-CLASS FUSION FOLLOWING TREATMENT WITH A TYROSINE KINASE INHIBITOR: PRELIMINARY DATA FROM UKALL2011

EHA Library, Anthony Moorman, 294937

TISAGENLECLEUCEL FOR PEDIATRIC/YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY REPORT OF B2001X FOCUSING ON PRIOR EXPOSURE TO BLINATUMOMAB AND INOTUZUMAB

EHA Library, Andre Baruchel, 294938

ALLCAR19: UPDATED DATA USING AUTO1, A NOVEL FAST-OFF RATE CD 19 CAR IN RELAPSED /REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA

EHA Library, Claire Roddie, 294939

DISRUPTION OF SERINE METABOLISM IS A NOVEL THERAPEUTIC STRATEGY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA

EHA Library, Stefan Bjelosevic, 294940

MIR-125B-MEDIATED TARGETING OF ARID3A PROMOTES THE PROGRESSION OF MYELOID LEUKEMIA

EHA Library, Oriol Alejo-Valle, 294941

HIF2ALPHA PARTAKES TO AML DIFFERENTIATION BLOCKADE, AND ITS INHIBITION DRIVES AML DIFFERENTIATION

EHA Library, Daniela Magliulo, 294942

THROMBOPOIETIN RECEPTOR ACTIVATION BY A DOWN SYNDROME MYELOID LEUKEMIA VARIANT OF THE COMMON BETA CHAIN OF THE IL3, IL5 AND GM-CSF SIGNALLING COMPLEXES

EHA Library, Leila Varghese, 294943

ATF3 REGULATES SERINE SYNTHESIS AND CATABOLISM TO SUPPORT AGGRESSIVE SUB-TYPES OF ACUTE MYELOID LEUKEMIA

EHA Library, Stephen Sykes, 294944

ELUCIDATION OF THE ONCOGENIC EVI1 SUPERENHANCER COMPLEX IN INV(3)/T(3;3) LEUKEMIA

EHA Library, Sandra Kiehlmeier, 294945

A SINGLE NUCLEOTIDE POLYMORPHISM OF THE TRANSCRIPTION FACTOR GROWTH FACTOR INDEPENDENCE 1 (GFI1) ACCELERATES AML EVOLUTION AND SENSITIZES AML CELLS TO TREATMENT WITH DNA REPAIR INHIBITORS

EHA Library, Daria Frank, 294946

CONCURRENT LOSS OF BCOR AND DNMT3A PROMOTES ACUTE ERYTHROID LEUKEMIA (AEL) IN MICE

EHA Library, Paolo Sportoletti, 294947

PAUSED TRANSCRIPTION, A NOVEL MIR139 SILENCING MECHANISM DOWNSTREAM OF MLL-AF9 IN ACUTE MYELOID LEUKEMIA

EHA Library, Christiaan J. Stavast, 294948

A MOUSE MODEL REVEALING THE TUMOR SUPPRESSIVE ACTIVITY OF GATA2

EHA Library, Avigail Rein, 294949

NOVEL INSIGHTS INTO GENOMIC CLASSIFICATION AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA BASED ON A PAN-EUROPEAN PUBLIC-PRIVATE PARTNERSHIP, THE HARMONY ALLIANCE

EHA Library, Lars Bullinger, 294950

THE NATURAL HISTORY AND FITNESS LANDSCAPE OF CLONAL HEMATOPOIESIS

EHA Library, Margarete Fabre, 294951

EXPRESSION OF THE EPITHELIAL TO MESENCHYMAL TRANSITION MODULATOR SNAI1 IN ACUTE MYELOID LEUKEMIA - A MODEL OF LSD1 CORRUPTION

EHA Library, Catherine Carmichael, 294952

FUNCTIONAL CHARACTERIZATION OF PRE-LEUKEMIC HEMATOPIOETIC CELLS

EHA Library, Liran Shlush, 294953

PATIENT-DERIVED XENOGRAFT MODELS OF ACUTE MYELOID LEUKEMIA FOR THE PRECLINICAL CHARACTERIZATION OF CD33.CAR-CIK CELLS ENGINEERED BY USING A LATEST VERSION OF THE SLEEPING BEAUTY TRANSPOSON SYSTEM

EHA Library, Maria Caterina Rotiroti, 294954

A SINGLE VERSUS FRACTIONATED SCHEDULE OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH DAUNORUBICIN / ARA-C AS INDUCTION THERAPY IN OLDER PATIENTS WITH AML: RESULTS FROM THE UK NCRI AML18 TRIAL

EHA Library, Nigel Russell, 294955